#guggenheim
Latest news and interesting information about guggenheim.
ERock Targets $5B Valuation in US IPO
ERock targets up to $5 billion valuation in its US IPO. The natural gas generator maker plans to raise $641.9 million.
CrowdStrike stock hits all-time high at 729.69 USD
CrowdStrike stock hits all-time high at 729.69 USD, market cap $185.22B. Analyst updates and company news. Read more on Bond.az.
Monte Rosa COO sells $43,500 in stock
Monte Rosa COO Jennifer Champoux sold $43,500 in stock. Shares surged 378% but trade above Bond.az Fair Value, indicating potential overvaluation.
Guggenheim Reiterates Neutral on CrowdStrike Stock
Guggenheim maintains Neutral rating on CrowdStrike (CRWD) citing valuation. Read analysis on stock performance and outlook.
JPMorgan Initiates Larimar at Overweight
JPMorgan starts Larimar Therapeutics at Overweight with $9 target. Stock at $3.47. Key developments on nomlabofusp.
Morgan Stanley Initiates Avalyn Pharma with Overweight
Morgan Stanley initiates Avalyn Pharma with Overweight rating and $53 target. The inhaled therapies AP01 and AP02 show promise in pulmonary fibrosis.
Monte Rosa director sells $180,100 of stock
Monte Rosa director Anthony Manning sold 10,000 shares for $180,100 at $18.01 each. The company reported positive prostate cancer drug trial results.
Assembly Biosciences prices $100M stock offering at $26.50
Assembly Biosciences prices $100 million stock offering at $26.50 per share. Gilead Sciences among investors. Proceeds for clinical development.
JPMorgan Raises Spotify Target to $650 on AI Deal
JPMorgan raised Spotify's target to $650 after AI deal and 2030 goals. Strong margin targets and growth prospects highlighted.
Enliven CMO sells $198,971 in stock
Enliven Therapeutics CMO Helen Collins sold $198,971 in stock. New data on ELVN-001 for CML released.
Deutsche Bank upgrades Elevance stock
Deutsche Bank upgraded Elevance Health to Buy with a $498 price target, citing stable managed care market. Strong Q1 results also boost confidence.
Guggenheim reiterates Buy rating on Okta stock
Guggenheim reiterates Buy rating on Okta stock with $138 price target. Analysts expect Q1 earnings to beat consensus.
Relay Therapeutics Launches $175M Stock Offering
Relay Therapeutics launches $175 million stock offering. See details on the offering, zovegalisib progress, and analyst ratings. Bond.az covers the latest.
Guggenheim Upgrades StubHub Stock on Reset
Guggenheim upgrades StubHub stock to Buy with a $12.50 price target, citing reset expectations and growth catalysts like the World Cup.
UBS Starts X-Energy Stock Coverage with Buy
UBS starts coverage on X-Energy stock with a buy rating and $40 target. The company's reactor model and growth potential are highlighted.
Shake Shack director buys $61,295 in stock
Shake Shack director Jeffrey Flug bought $61,295 worth of stock. Shares near 52-week low. Detailed analysis on Bond.az.
Piper Sandler Raises Biogen Target to $225
Piper Sandler raises Biogen price target to $225 from $214. Phase II trial of BIIB080 missed primary endpoint but showed slowing of clinical decline at lowest dose.
Biogen Stock: Alzheimer Drug Shows Promise
Biogen's Alzheimer drug diranersen shows positive Phase 2 results. Stock analysis and future outlook from Bond.az.
Guggenheim Raises StubHub Target on Strong Q1
Guggenheim lifted StubHub's price target after strong Q1 results, citing revenue and EBITDA beats.
...